Müller-Vahl KR - Search Results

1

Immunity in Gilles de la Tourette-Syndrome: Results From a Cerebrospinal Fluid Study.

Baumgaertel C, Skripuletz T, Kronenberg J, Stangel M, Schwenkenbecher P, Sinke C, Müller-Vahl KR, Sühs KW. Baumgaertel C, et al. Front Neurol. 2019 Jul 4;10:732. doi: 10.3389/fneur.2019.00732. eCollection 2019. Front Neurol. 2019. PMID: 31333575 Free PMC article.

2

Dopamine transporter binding in Gilles de la Tourette syndrome.

Müller-Vahl KR, Berding G, Brücke T, Kolbe H, Meyer GJ, Hundeshagen H, Dengler R, Knapp WH, Emrich HM. Müller-Vahl KR, et al. J Neurol. 2000 Jul;247(7):514-20. doi: 10.1007/pl00007806. J Neurol. 2000. PMID: 10993492

3

Excessive action monitoring in Tourette syndrome.

Johannes S, Wieringa BM, Nager W, Müller-Vahl KR, Dengler R, Münte TF. Johannes S, et al. J Neurol. 2002 Aug;249(8):961-6. doi: 10.1007/s00415-002-0657-9. J Neurol. 2002. PMID: 12195438

4

Altered modulation of intracortical excitability during movement preparation in Gilles de la Tourette syndrome.

Heise KF, Steven B, Liuzzi G, Thomalla G, Jonas M, Müller-Vahl K, Sauseng P, Münchau A, Gerloff C, Hummel FC. Heise KF, et al. Brain. 2010 Feb;133(Pt 2):580-90. doi: 10.1093/brain/awp299. Epub 2009 Dec 11. Brain. 2010. PMID: 20008030

5

Health-related quality of life in patients with Gilles de la Tourette's syndrome.

Müller-Vahl K, Dodel I, Müller N, Münchau A, Reese JP, Balzer-Geldsetzer M, Dodel R, Oertel WH. Müller-Vahl K, et al. Mov Disord. 2010 Feb 15;25(3):309-14. doi: 10.1002/mds.22900. Mov Disord. 2010. PMID: 20063404

6

Cost of illness in patients with Gilles de la Tourette's syndrome.

Dodel I, Reese JP, Müller N, Münchau A, Balzer-Geldsetzer M, Wasem J, Oertel WH, Dodel R, Müller-Vahl K. Dodel I, et al. J Neurol. 2010 Jul;257(7):1055-61. doi: 10.1007/s00415-010-5458-y. Epub 2010 Feb 24. J Neurol. 2010. PMID: 20179960

7

Oligoclonal bands in cerebrospinal fluid in patients with Tourette's syndrome.

Wenzel C, Wurster U, Müller-Vahl KR. Wenzel C, et al. Mov Disord. 2011 Feb 1;26(2):343-6. doi: 10.1002/mds.23403. Epub 2010 Oct 19. Mov Disord. 2011. PMID: 20960488

8

Treatment of Tourette syndrome with cannabinoids.

Müller-Vahl KR. Müller-Vahl KR. Behav Neurol. 2013;27(1):119-24. doi: 10.3233/BEN-120276. Behav Neurol. 2013. PMID: 23187140 Free PMC article. Review.

9

Event-related brain potentials show changed attentional mechanisms in Gilles de la Tourette Syndrome.

Johannes S, Weber A, Müller-Vahl KR, Kolbe H, Dengler R, Münte TF. Johannes S, et al. Eur J Neurol. 1997 Mar;4(2):152-61. doi: 10.1111/j.1468-1331.1997.tb00321.x. Eur J Neurol. 1997. PMID: 24283908

10

Patients with Gilles de la Tourette syndrome have widespread personality differences.

Trillini MO, Müller-Vahl KR. Trillini MO, et al. Psychiatry Res. 2015 Aug 30;228(3):765-73. doi: 10.1016/j.psychres.2015.04.043. Epub 2015 May 29. Psychiatry Res. 2015. PMID: 26112450

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

191 results

Search Page